Effects of long-term macrolide therapy at low doses in stable COPD

References

• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–963. doi:10.1136/thoraxjnl-2011-20151822684094
   PubMed Web of Science ®Google Scholar
• Ferkol T, Schrau fnagel D. The global burden of respiratory disease. Ann Am Thorac Soc 2014;11:404–406. doi:10.1513/AnnalsATS-201311-405PS.
   Google Scholar
• Marchetti N, Criner GJ, Albert RK. Preventing acute exacerbations and hospital admissions in COPD. Chest. 2013;143:1444–1454. doi:10.1378/chest.12-180123648908
   PubMed Web of Science ®Google Scholar
• Criner GJ, Bourbeau J, Diekemper RL, et al. Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:883–893. doi:10.1378/chest.14-167725320966
   PubMed Web of Science ®Google Scholar
• Donath E, Chaudhry A, Hernandez-Aya LF, et al. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with chronic obstructive pulmonary disease. Respir Med. 2013;107:1385–1392. doi:10.1016/j.rmed.2013.05.00423768735
   PubMed Web of Science ®Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–2365. doi:10.1056/NEJMoa080193619038881
   PubMed Web of Science ®Google Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflmmation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121. doi:10.1164/rccm.200506-859OC16484677
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001;120:730–733.11555501
   PubMed Web of Science ®Google Scholar
• Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med. 2005;99:208–215.15715188
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–1147. doi:10.1164/rccm.200801-145OC18723437
   PubMed Web of Science ®Google Scholar
• He ZY, Ou LM, Zhang JQ, et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration. 2010;80:445–452. doi:10.1159/00032137420881376
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698. doi:10.1056/NEJMoa091038321864166
   PubMed Web of Science ®Google Scholar
• Berkhof FF, Doornewaard-Ten Hertog NE, Uil SM, et al. Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res. 2013;14:125. doi:10.1186/1465-9921-14-1924229360
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368. doi:10.1016/S2213-2600(14)70019-024746000
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014;9:e105609. doi:10.1371/journal.pone.010560925148049
   PubMed Web of Science ®Google Scholar
• Shafuddin E, Mills GD, Holmes MD, et al. A double-blind, randomised, placebocontrolled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. J Negat Results Biomed. 2015;14:15. doi:10.1186/s12952-015-0034-826346300
   PubMedGoogle Scholar
• Ra SW, Sze MA, Lee EC, et al. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respir Res. 2017;18:109. doi:10.1186/s12931-017-0594-x28558695
   PubMed Web of Science ®Google Scholar
• Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir. 2005;25:640–646. doi:10.1183/09031936.05.00047504
   PubMed Web of Science ®Google Scholar
• Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60:293–300. doi:10.1136/thx.2004.02794615790984
   PubMed Web of Science ®Google Scholar
• Wang P, Yang J, Yang Y, et al. Effect of azithromycin in combination with simvastatin in the treatment of chronic obstructive pulmonary disease complicated by pulmonary arterial hypertension. Pak J Med Sci. 2017;33(2):260–264. doi:10.12669/pjms.332.1171728523018
   PubMed Web of Science ®Google Scholar
• Wouters E, Groenewegen K, Dentener M, et al. Systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(8):626–634. doi:10.1513/pats.200706-071TH18073394
   PubMedGoogle Scholar
• Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci USA. 2014;111:2247–2252. doi:10.1073/pnas.132226911124390544
   PubMed Web of Science ®Google Scholar
• Shen H, Shen C. Research progress of immunomodulatory effects of macrolide drugs. Sect Respirat Syst Foreign Med Sci. 2005;25(11):818–821.
   Google Scholar
• Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax. 2002;57:189–190. doi:10.1136/thorax.57.3.18911867820
   PubMed Web of Science ®Google Scholar
• Rubin BK. Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med. 2004;117:Suppl 9A, 2–4.
   Web of Science ®Google Scholar
• Pomares X, Monton C, Espasa M, Casabon J, Monsó E, Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis. 2011;6:449–456. doi:10.2147/COPD.S2365522003290
   PubMed Web of Science ®Google Scholar
• Gillis RJ, Iglewski BH. Azithromycin retards Pseudomonas K.aeruginosa biofilm formation. J Clin Microbiol. 2004;42:5842–5845. doi:10.1128/JCM.42.12.5842-5845.200415583321
   PubMed Web of Science ®Google Scholar
• Starner TD, Shrout JD, Parsek MR, et al. Subinhibitory concentrations of azithromycin decrease nontypeable haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother. 2008;1(52):137–145. doi:10.1128/AAC.00607-07
   Web of Science ®Google Scholar
• Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):1–13. doi:10.1371/journal.pone.0121257
   Web of Science ®Google Scholar
• Herath SC, Normansell R, Maisey S, et al. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;10:CD009764.30376188
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503–1508. doi:10.1164/rccm.201306-1150OC24779680
   PubMed Web of Science ®Google Scholar
• Moj D, Hanke N, Britz H, et al. Clarithromycin midazolam, and digoxin: application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J. 2017;19(1):298–312. doi:10.1208/s12248-016-0009-927822600
   PubMed Web of Science ®Google Scholar
• Hughes J, Crowe A. Inhibition of P-glycoprotein–mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010;113:315–324.20724802
   PubMed Web of Science ®Google Scholar
• Gomes CM, van Paassen H, Romeo S, et al. Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nuclear Med Biol. 2006;33:831–840. doi:10.1016/j.nucmedbio.2006.07.011
   Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890. doi:10.1056/NEJMoa100383322591294
   PubMed Web of Science ®Google Scholar
• Qiu S, Xiaoning Z. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2017;11(3):147–155. doi:10.1177/175346581668267728030992
   PubMed Web of Science ®Google Scholar